Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Office of Research & Development

print icon sign up for VA Research updates

Funded Project Details - FY2021




Project Number:

I01CX001449-01A1
Title: Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease
Principal Investigator:

Mark S. Segal

Location: Gainesville, FL
Congressional District Code: 3
Research Service: Clinical Science R&D
Project Period: October 2017 - September 2022
FY 2021 Funding Amount: $0
Total Award Amount
(all years):
$401,473
Abstract: View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER


Excerpt:

Erythropoietin is the most widely prescribed cytokine, yet the benefits and potential side effects of different dosing regimens are poorly understood. Clinically, it is now recognized that erythropoietin administered at high doses results in an increased probability of cancer recurrence and in patients with chronic kidney disease, an increased risk of morbidity and mortality from heart disease and stroke. However, the mechanisms that mediate this increased risk of cardiovascular disease is not k...



Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.